Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

Coherus BioSciences, Inc. (CHRS): $7.54

-0.12 (-1.57%)

POWR Rating

Component Grades













Add CHRS to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where CHRS ranks best; there it ranks ahead of 87.36% of US stocks.
  • CHRS's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • CHRS's current lowest rank is in the Sentiment metric (where it is better than 3.74% of US stocks).

CHRS Stock Summary

  • With a one year PEG ratio of 1.28, Coherus BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 6.36% of US stocks.
  • Over the past twelve months, CHRS has reported earnings growth of -268.38%, putting it ahead of merely 7.23% of US stocks in our set.
  • Revenue growth over the past 12 months for Coherus BioSciences Inc comes in at -31.37%, a number that bests only 5.34% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Coherus BioSciences Inc, a group of peers worth examining would be AGLE, MCRB, CRIS, VYGR, and SURF.
  • CHRS's SEC filings can be seen here. And to visit Coherus BioSciences Inc's official web site, go to

CHRS Valuation Summary

  • CHRS's price/sales ratio is 3.1; this is 18.42% lower than that of the median Healthcare stock.
  • Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.
  • Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.

Below are key valuation metrics over time for CHRS.

Stock Date P/S P/B P/E EV/EBIT
CHRS 2021-08-31 3.1 7.8 -7.4 -9.3
CHRS 2021-08-30 3.1 7.8 -7.3 -9.2
CHRS 2021-08-27 3.1 7.7 -7.3 -9.1
CHRS 2021-08-26 3.1 7.7 -7.3 -9.2
CHRS 2021-08-25 3.0 7.6 -7.2 -9.0
CHRS 2021-08-24 3.0 7.5 -7.1 -8.9

CHRS Growth Metrics

    Its 4 year price growth rate is now at -13.23%.
  • Its year over year net cashflow from operations growth rate is now at 43.74%.
  • The 3 year price growth rate now stands at -16.15%.
Over the past 34 months, CHRS's revenue has gone up $289,453,000.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 326.551 -37.432 -287.1
2021-09-30 363.599 48.014 -231.667
2021-06-30 394.647 81.656 -165.206
2021-03-31 442.678 142.035 -76.275
2020-12-31 475.824 154.145 132.244
2020-09-30 489.261 138.731 161.763

CHRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CHRS has a Quality Grade of B, ranking ahead of 82.07% of graded US stocks.
  • CHRS's asset turnover comes in at 0.513 -- ranking 78th of 682 Pharmaceutical Products stocks.
  • CPRX, XTNT, and VIVO are the stocks whose asset turnover ratios are most correlated with CHRS.

The table below shows CHRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.513 0.886 -0.228
2021-03-31 0.572 0.913 -0.075
2020-12-31 0.664 0.921 0.250
2020-09-30 0.803 0.931 0.332
2020-06-30 0.995 0.936 0.477
2020-03-31 1.206 0.950 0.576

CHRS Price Target

For more insight on analysts targets of CHRS, see our CHRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.71 Average Broker Recommendation 1.57 (Moderate Buy)

CHRS Stock Price Chart Interactive Chart >

Price chart for CHRS

CHRS Price/Volume Stats

Current price $7.54 52-week high $19.32
Prev. close $7.66 52-week low $7.24
Day low $7.36 Volume 867,986
Day high $7.81 Avg. volume 941,963
50-day MA $10.21 Dividend yield N/A
200-day MA $14.17 Market Cap 583.77M

Coherus BioSciences, Inc. (CHRS) Company Bio

Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.

CHRS Latest News Stream

Event/Time News Detail
Loading, please wait...

CHRS Latest Social Stream

Loading social stream, please wait...

View Full CHRS Social Stream

Latest CHRS News From Around the Web

Below are the latest news stories about Coherus BioSciences Inc that investors may wish to consider to help them evaluate CHRS as an investment opportunity.

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2021 Results - Earnings Call Transcript

Coherus BioSciences, Inc. (CHRS) Q4 2021 Earnings Conference Call February 17, 2022 5:00 PM ET Company Participants Denny Lanfear - President, Chief Executive Officer and Chairman McDavid Stilwell - Chief Financial Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Conference Call Participants Salim Syed -...

SA Transcripts on Seeking Alpha | February 18, 2022

Coherus BioSciences'' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices

Coherus BioSciences Inc''s (NASDAQ: CHRS ) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. The company posted an adjusted EPS … Full story available on

Benzinga | February 18, 2022

Coherus BioSciences Non-GAAP EPS of -$0.46 beats by $0.08, revenue of $73.37M misses by $9.24M

Coherus BioSciences press release (NASDAQ:CHRS): Q4 Non-GAAP EPS of -$0.46 beats by $0.08. Revenue of $73.37M (-33.6% Y/Y) misses by $9.24M. Cash and cash equivalents were $417.2 million as of December 31, 2021, compared to $541.2 million as of December 31, 2020.  2022 Guidance: Coherus projects combined R&D and SG&A expenses...

Seeking Alpha | February 17, 2022

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

– YUSIMRY ™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI ™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA ® on-body injector and additional toripalimab indications – – UDENYCA ® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 – – Conference call and webcast today at 5:00 p.m. ET –

GlobeNewswire | February 17, 2022

Coherus BioSciences (CHRS) Q4 2021 Earnings Call Transcript

CHRS earnings call for the period ending December 31, 2021.

The Motley Fool | February 17, 2022

Read More 'CHRS' Stories Here

CHRS Price Returns

1-mo -18.75%
3-mo -35.72%
6-mo -58.95%
1-year -42.75%
3-year -60.67%
5-year -62.77%
YTD -52.76%
2021 -8.17%
2020 -3.47%
2019 98.95%
2018 2.84%
2017 -68.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7002 seconds.